# US 8,569,240 B2 · Methods of preventing or treating brain diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,569,240 B2
- Document ID: US8569240B2
- Status: Granted
- Kind: B2
- Application number: 13/209,437
- Filed: 2011-08-14
- Published: 2012-02-16
- Granted: 2013-10-29
- Earliest claimed: 2008-01-25
- Assignees: Regeron, Inc.
- Applicants: Heejae Lee; Jong-Seon Byun; Kyung Young Lee; Dahlkyun Oh
- Inventors: Heejae Lee; Jong-Seon Byun; Kyung Young Lee; Dahlkyun Oh
- Web page: https://patentgrep.com/patent/US8569240B2

## CPC

- C07K 14/47: from mammals
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A61K 38/22: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

The present invention relates to methods for preventing or treating neurological diseases, particularly brain diseases, and improving cognitive functions using a composition comprising stanniocalcin 2 as an active ingredient.

## Claims

### Claim 1

A method for improving a cognitive function of a subject, the method comprising administering to a subject a therapeutically acceptable amount of a composition comprising as an active ingredient stanniocalcin 2 having an amino acid sequence of SEQ ID NO:1.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the subject suffers from a neurodegenerative disease.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the composition is administered orally or parenterally.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the composition is administered orally or parenterally.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the cognitive function is learning ability, memory or concentration.

### Claim 6

A method for improving a cognitive function of a subject, the method comprising administering to the subject a therapeutically acceptable amount of a composition comprising as an active ingredient stanniocalcin 2 having an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO:2.

### Claim 7 (depends on 6)

The method of claim 6, wherein the subject suffers from a neurodegenerative disease.

### Claim 8 (depends on 6)

The method according to claim 6, wherein the composition is administered orally or parenterally.

### Claim 9 (depends on 7)

The method according to claim 7, wherein the composition is administered orally or parenterally.

### Claim 10 (depends on 6)

The method according to claim 6, wherein the cognitive function is learning ability, memory or concentration.